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Abstract 
We report that activation of phospholipase C (PLC) by cross-linking of the platelet low-affinity Fey receptor II (FcyRII) is inhibited by two 
structurally distinct tyrosine kinase inhibitors, staurosporine and ST271. This contrasts with PLC activation induced by thrombin and U46619, a 
thromboxane mimetic, whose receptors have seven transmembrane domains characteristic of G-protein coupled receptors. Several proteins undergo 
phosphorylation on tyrosine on FcyRII cross-linking upstream of protein kinase C (PKC), Ca” and aggregation, including the FcyRII itself. The 
role of FcyRII phosphorylation in the regulation of PLC is discussed. 
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1. Introduction 
As well as their major role in hemostasis, platelets 
participate in the immune response, forming mi- 
crothrombi over the surface of immune complexes lead- 
ing to local inflammation [11. The interaction of platelets 
with immune complexes is mediated by a low-affinity Fc 
receptor, FcyRII (CD32), on the platelet surface [2]. 
Cross-linking of FcyRII using specific antibodies mimics 
the effect of the immune complex and leads to activation 
of PLC [3]. Cross-linking of FcyRII on the human mon- 
ocytic cell line, U937, leads to a rapid transient phospho- 
rylation of PLCy-1 on tyrosine residues and the forma- 
tion of inositol phosphates [4]. In the present study we 
have investigated whether the FcyRII in platelets regu- 
lates PLC through a tyrosine kinase-mediated pathway. 
2. Materials and methods 
2.1. Materials 
Monoclonal antibody (mAb) IV3 was purchased from Madarex Inc. 
(New Hampshire, USA). mAb PY20 was purchased from ICN Flow 
(High Wycombe, Bucks. UK). Ro 31-8220 was a gift from Roche 
Products (Welwyn Garden City, Herts., UK). Staurosporine, U46619, 
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bovine serum albumin (fraction V), Tween-20 and sheep F(ab’), raised 
against mouse IgG (M-1522) were purchased from Sigma (Poole, 
Dorset, UK). Nonidet P40 was purchased from BDH (Poole, UK). 
ST271 was kindly donated by the Wellcome Foundation. Horseradish 
peroxidase-conjugated sheep anti-mouse IgG, secondary antibody 
(NA931), ECL reagents and myo-[‘Hlinositol (sp.act. 18.2 Ci/mMol) 
were from Amersham International (Cardiff, UK). All other reagents 
were of Analytical grade. 
2.2. Platelet isolation, stimulation and inositol phosphates 
Human platelets were isolated from drug-free volunteers on the day 
of the experiment as previously described [5] and resuspended at a 
concentration of between 2-8 x lO*/ml. Platelets were pre-labelled with 
[‘Hlinositol for 3 h and inositol phosphates measured as previously 
described [5]. In some experiments, platelets (8 x lO*/ml) were incu- 
bated with the intracellular Ca” chelator BAPTA-AM (40 PM) for 15 
min. Platelets were resuspended ina modified Tyrode buffer containing 
indomethacin (10 PM) and EGTA (1 mM) and all experimentation was 
performed at 37°C with continuous stirring [5]. 
The FcyRII was stimulated by cross-linking with mAb IV3 (1 &ml) 
and F(ab’)z anti-mouse IgG (30 pg/ml), the mAb IV3 was added 60 s 
before F(ab’),, the latter time being taken as the start of stimulation. 
The protein kinase inhibitors staurosporine and Ro 31-8220 were given 
60 s before agonist stimulation while ST271 was given 10 min before 
agonist addition. 
2.3. Immunoprecipitation and immunoblotting 
Following stimulation, platelets (8 x 10*/l ml) were lysed at 4°C for 
30 min with an equal volume of ice-cold extraction buffer consisting of 
Nonidet P-40 (2%), NaCl (300 mM), Tris (20 mM), PMSF (1 mM), 
EDTA (10 mM), Na,VO, (2 mM) at pH 7.3. Sufficient antibody was 
added to controls after lysis to make the antibody levels equivalent in 
all samples. Samples were diluted 1:20 in TBS-T (Tris, 20 mM; NaCl, 
137 mM; Tween-20, 0.1% (v/v)) containing: bovine serum albumin (2 
mg/ml), PMSF (1 mM) and EDTA (1 mM). Insoluble cell debris was 
removed by centrifugation at 3,000 x g for 30 min. mAb IV.3 (2 pg) was 
then added to the supernatant fraction, followed 30 min later by 40 ~1 
of a suspension of protein A-sepharose CL 4B which had been hydrated 
in TBS-T containing 10% (w/v) bovine serum albumin and sodium 
azide (0.05%, w/v). After an overnight incubation, the protein A-sepha- 
rose CL 4B was pelleted by centrifugation at 3,000 x g for 10 min and 
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Fig. 1. The effect of staurosporine (10 PM), Ro 31-8220 (10 PM) and ST271 (100 PM) on the formation of inositol phosphates timulated by: (A) 
thrombin (1 unit/ml), (B) U46619 (20 PM), and (C) FcyRII cross-linking (as detailed in section 2). Platelets were incubated with kinase inhibitor 
then exposed to the above stimuli for 5 min. The data is expressed as mean f S.E.M. of the percentage stimulation in the absence of the inhibitor. 
The response to each stimulus expressed as a percentage ofbasal + S.E.M. were: thrombin, 1463 + 55 (n = 7); U46619,531 + 15 (n = 11); and FcyRII 
cross-linking, 829 f 67 (n = 6). The basal value was 123 f 10 (n = 35) dpm. 
then washed four times in 50 ml of TBS-T containing PMSF (1 mM) 
and EDTA (1 mM). Immunoprecipitated protein was resolved by SDS 
PAGE (12%) and Western blotted [6]. The Western blot was probed 
initially with HRP-conjugated secondary antibody and ECL detection 
was used to identify bands of direct secondary antibody binding. The 
blot was then probed for phosphotyrosine using mAb PY20 followed 
by reprobing with the secondary antibody and ECL detection. 
2.4. Analysis of results 
Results are expressed as mean + S.E.M. from at least three exper- 
iments performed in quadruplicate. Statistical significance was indi- 
cated using Student’s t-test. 
3. Results 
3.1. Measurement of inositol phosphates 
Staurosporine (10 PM) had no significant effect on the 
formation of inositol phosphates induced by thrombin or 
the thromboxane mimetic, U46619 (Fig. 1). In contrast, 
it completely blocked the response induced by FcyRIl 
cross-linking (Fig. 1). The structural derivative of stauro- 
sporine, Ro 31-8220 (10 PM), which exhibits a high 
degree of selectivity for PKC over tyrosine kinases in 
platelets [6], did not reduce FcyRII stimulated inositol 
phosphate production and potentiated the response to 
thrombin and U46619 (Fig. 1). The tyrphostin, ST271 
(100 PM), which is claimed to be a more selective inhib- 
itor of tyrosine kinases, also caused complete inhibition 
of formation of inositol phosphates induced by FcyRII 
cross-linking, but also induced a small (C 30%) but sig- 
nificant inhibition of the response to thrombin and U46619 
(Fig. 1). 
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Fig. 2. The effect of kinase inhibitors and intracellular Ca” chelation on protein tyrosine phosphorylation stimulated by thrombin (1 unit/ml) in (A), 
lanes 2-5; and FcyRII cross-linking (as detailed in section 2) in (B), lanes 2-5. Lane 1 in each figure shows basal phosphorylation. Platelets resuspended 
at a density of 8 x 108/ml were treated with: lane 3, staurosporine (10 PM); lane 4, Ro31-8220 and BAPTA-AM (as detailed in section 2); and lane 
5, ST271 (300 PM). They were then exposed to the above stimuli for 2 min. SDS-12% PAGE, and anti-phosphotyrosine immunoblotting were as 
detailed in section 2. The results are representative of three similar experiments. 
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3.2. Measurement of protein tyrosine phosphorylation 
Fig. 2 demonstrates the thrombin and FcyRII cross- 
linking induce tyrosine phosphorylation of several pro- 
teins throughout the lane of the gel. The increase in 
tyrosine phospho~lation is inhibited completely by stau- 
rosporine (10 PM) and ST271 (300 PM) (Fig. 2). In order 
to investigate whether the thrombin-induced increase in 
protein tyrosine phosphorylation was mediated down- 
stream of PKC and Ca2’, we used a combination of the 
PKC inhibitor, Ro 31-8220 (10 PM), and the intracellu- 
lar Ca2’ chelator, BAPTA-AM (40 PM). In preliminary 
experiments, this concentration of BAPTA-AM inhib- 
ited the rise in intracellular Ca2’ induced by thrombin by 
greater than 90%. Under these conditions, thrombin did 
not stimulate detectable tyrosine phosphorylation 
(Fig. 2). In marked contrast, Fc)lRII cross-linking in the 
presence of Ro 31-8220 and BAPTA-AM resulted in a 
marked increase in tyrosine phosphorylation of two pro- 
teins of 38 and 71 kDa, and minor changes in several 
other proteins (Fig. 2) suggesting that these increases 
occur upstream of PKC and Ca2’. Interestin~y, throm- 
bin induces significant phospho~lation of a 71 but not 
a 38 kDa protein in the absence of Ro 31-8220 and 
BAPTA-AM. 
It has previously been reported that the FcyRII is 
phosphorylated on tyrosine residues following cross- 
linking of the receptor [7J Fig. 3 confirms that the 
FcyRII is phosphorylated following receptor cross-link- 
ing and demonstrates that this is unaffected by pre-treat- 
ment with a combination of Ro 318220 and BAPTA- 
AM. The mobility of the 40 kDa phosphorylated FcyRII 
does not correspond with the phosphorylated 38 kDa 
band described in Fig. 2. 
4. Discussion 
4.1. Role of tyrosine p~osphory~atio~ in the generation of 
inositol phosp~tes 
We have presented pharmacological evidence that 
stimulation of platelet PLC activity by FcyRII cross- 
linking is dependent on tyrosine phosphorylation. Two 
structurally dissimilar tyrosine kinase inhibitors, the in- 
dole carbazole-based staurospo~ne [8] and the styryl- 
based ST271 [9], inhibited completely the formation of 
inositol phosphates induced by FcyRII cross-linking. In 
contrast, staurosporine did not alter the formation of 
inositol phosphates induced by the G protein linked 
[ 10,l l] receptor stimuli thrombin and U46619 while 
ST271 induced a small degree of inhibition. Stauro- 
sporine has also been shown to inhibit the increase in 
intracellular Ca” stimulated in platelets by wheat germ 
agglutinin [12], whose mechanism of activation involves 
the non-specific cross-linking of surface glycoprotein. 
These results are consistent with the reported tyrosine 
kDa 
125- 
94. 
72- 
51- 
35. 
17 
t 
IS 
-heavy 
chain 
tFcyRI1 
Fig. 3. Tyrosine phosphorylation of FcyRII in response to receptor 
cross linking is neither dependent on PKC activity nor on the elevation 
of the intra-cellular Ca” concentration. The figure shows an anti- 
phosphotyrosine immunoblot of FcyRII immunoprecipitated from: 
lane I, untreated platelets; lane 2, platelets timulated by cross-linking 
FcyRII (60 s); and lane 3, platelets pretreated with Ro31-8220 and 
BAPTA-AM, then stimulated as in lane 2. Stimulation and use of 
inhibitors, immunoprecipitation, SDS-PAGE, and anti-phosphoty- 
rosine immunoblotting were as detailed in section 2. 
phospho~lation of PLCy-1 in U937 cells activated by 
FcyRII cross-linking ]4]. 
The inhibitory effect of ST271 on the activation of 
PLC by thrombin and U46619 could represent a non- 
selective action resulting from the relatively high concen- 
tration of ST271 required to achieve full in~bition of 
tyrosine phospho~lation. Consistent with this, tyr- 
phostins have been reported to inhibit oxidative phos- 
phorylation in isolated fat cells [9]. Alternatively, 
however, the inhibitory effect of ST271 may reflect par- 
ticipation of PLCy-1 in thrombin and U46619-induced 
formation of inositol phosphates, an effect that is likely 
to occur downstream of PKC and Ca2+. This possibility 
provides an explanation for the paradoxical action of Ro 
31-8220 on thrombin- and U46619-induced formation of 
inositol phosphates compared with the effect of stauro- 
sporine. Both Ro 31-8220 and staurosporine are potent 
inhibitors of PKC and yet only Ro 31-8220 induces po- 
tentiation of the formation of inositol phosphates by 
these two receptor stimuli, an effect that is likely to be 
mediated by inhibition of the negative feedback action 
of PKC on G protein receptor-induced activation of PLC 
]13]. The absence of a similar potentiation effect medi- 
ated by staurosporine may represent a cancelling out of 
the negative feedback action of PKC, which would lead 
to an increase in PLC activity, and an inhibition of tyro- 
sine kinase activation of PLC. In contrast, ST271 has no 
effect on PKC activity and so only the inhibitory effect 
on tyrosine kinase activity is observed. 
18 
4.2. Mechanism of FcyZUZ signaling 
In order to identify proteins that are uniquely tyrosine 
phosphorylated by FcyRII cross-linking relative to 
thrombin and U46619 receptors, we have employed a 
strategy to block increases in tyrosine phosphorylation 
that occur downstream of PKC and Ca” through the 
combined use of Ro 318220 and BAPTA-AM. This has 
led to identification of the prominent tyrosine phospho- 
rylation of two proteins of 38 and 71 kDa, along with a 
number of minor proteins, which occur upstream of 
PKC and Ca*‘. In view of the fact that many tyrosine 
kinases undergo autophosphorylation, and that several 
tyrosine kinases are present in platelets in remarkably 
high levels (e.g. SYC and syk which make up 0.3% [14] and 
0.15% [15] of platelet protein, respectively), the 38 and 
71 kDa bands may represent yrosine kinases. It is there- 
fore provocative that syk is approximately 70 kDa in size 
and that FcyRII is reported to activate syk in the human 
monocytic cell line THP-1 [16]. 
One of the minor proteins which undergoes tyrosine 
phosphorylation has been identified as FcyRII. This 
provides the potential for direct receptor regulation of a 
tyrosine kinase or PLCy-1 through interaction of the 
phosphotyrosine residue and an SH2 domain. Different 
SH2 domains have preference for different sequences 
neighbouring the phosphotyrosine. We have searched 
for a match between recently published SH2 domain 
sequence preferences [17] and the potential tyrosine 
phosphorylation sites on the cytoplasmic domain of 
FcyRIIA, the predominant subtype of FcyRII on plate- 
lets [18]. Human FcyRIIA has three tyrosine residues in 
its cytoplasmic domain [19] and the closest match found 
was in the sequence neighbouring tyrosine 310, YLTL, 
and the sequence preference of the N-terminal SH2 do- 
main of PLQ-1, YLDL. If tyrosine 3 10 undergoes phos- 
phorylation, and allowing for the degeneracy of SH2 
domain sequence preference, this may prove to be a 
binding site and ‘membrane anchor’ for PLCy- 1, bring- 
ing it in close proximity to its substrate in the membrane. 
Alternatively, we speculate that FcyRII phosphorylation 
enables the binding and activation of a separate tyrosine 
kinase, possibly syk, through an SH2 domain, which will 
then induce phosphorylation and activation of PLCy-1. 
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